File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease

TitleDouble-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease
Authors
Issue Date2004
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2004, v. 19 n. 4, p. 455-462 How to Cite?
AbstractBackground: Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population. Aim: To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease. Methods: Forty-four patients (male to female ratio, 27:17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period. Results: Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups. Conclusion: Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population.
Persistent Identifierhttp://hdl.handle.net/10722/77079
ISSN
2014 Impact Factor: 5.727
2013 SCImago Journal Rankings: 2.609
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLam, KFen_HK
dc.contributor.authorHuang, JQen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorWong, NYHen_HK
dc.contributor.authorLam, CLKen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T07:28:02Z-
dc.date.available2010-09-06T07:28:02Z-
dc.date.issued2004en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2004, v. 19 n. 4, p. 455-462en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77079-
dc.description.abstractBackground: Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population. Aim: To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease. Methods: Forty-four patients (male to female ratio, 27:17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period. Results: Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups. Conclusion: Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_HK
dc.subject.meshAnti-Ulcer Agents - administration & dosageen_HK
dc.subject.meshChina - ethnologyen_HK
dc.subject.meshCross-Over Studiesen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGastric Acidity Determinationen_HK
dc.subject.meshGastroesophageal Reflux - drug therapy - ethnologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHydrogen-Ion Concentrationen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - administration & dosage - analogs & derivativesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleDouble-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=19&issue=4&spage=455&epage=62&date=2004&atitle=Double-blind,+Randomized+Controlled+Study+to+Assess+the+Effects+of+Lansoprazole+30+mg+and+Lansoprazole+15+mg+on+24-h+Oesophageal+and+Intragastric+pH+in+Chinese+Subjects+with+Gastro-Oesophageal+Reflux+Diseaseen_HK
dc.identifier.emailLam, KF: hrntlkf@hkucc.hku.hken_HK
dc.identifier.emailLam, CLK: clklam@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityLam, KF=rp00718en_HK
dc.identifier.authorityLam, CLK=rp00350en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2004.01846.xen_HK
dc.identifier.pmid14871286en_HK
dc.identifier.scopuseid_2-s2.0-10744232346en_HK
dc.identifier.hkuros86283en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10744232346&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue4en_HK
dc.identifier.spage455en_HK
dc.identifier.epage462en_HK
dc.identifier.isiWOS:000188892300010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridLam, KF=8948421200en_HK
dc.identifier.scopusauthoridHuang, JQ=7403635051en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridWong, NYH=7202836655en_HK
dc.identifier.scopusauthoridLam, CLK=24755913900en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats